A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Latest Information Update: 04 Mar 2026
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms AWARD-PEDS PLUS
- Sponsors Eli Lilly and Company
Most Recent Events
- 20 Jan 2026 Planned End Date changed from 1 Jul 2026 to 1 Dec 2027.
- 20 Jan 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Dec 2027.
- 24 Jan 2025 Status changed from not yet recruiting to recruiting.